Damm-Welk Christine, Schieferstein Jutta, Schwalm Simone, Reiter Alfred, Woessmann Willi
Department of Paediatric Haematology and Oncology, Justus-Liebig University, Giessen, Germany.
Br J Haematol. 2007 Aug;138(4):459-66. doi: 10.1111/j.1365-2141.2007.06672.x. Epub 2007 Jun 29.
Quantification of occult circulating tumour cells in blood or bone marrow (BM) enables the identification of patients with a high risk for relapse in nucleophosmin/anaplastic lymphoma kinase (NPM-ALK)-positive anaplastic large cell lymphoma (ALCL). We have developed a flow cytometric (FCM) assay to quantify the rare ALK- and CD30-positive ALCL cells. When ALCL cells were admixed with normal peripheral blood or BM, ALK- and CD30-positive cells could be detected above background level at an added concentration of 10(-5) for all three cell lines tested. Sensitivity and costs of the assay were compared with quantitative real-time polymerase chain reaction (PCR) for NPM-ALK. The results of the FCM assay and quantitative PCR for NPM-ALK correlated. The sensitivity of the PCR exceeded that of the FCM by at least one log. Quantitative PCR was more time-consuming and expensive than FCM. Both methods were compared on BM or blood samples from 11 ALCL patients. FCM using antibodies against ALK and CD30 can sensitively and specifically detect the circulating ALCL cells in BM or blood. This method needs to be tested in a larger cohort of patients to determine whether it has sufficient sensitivity to be used as a substitute for quantitative PCR.
对血液或骨髓(BM)中隐匿循环肿瘤细胞进行定量分析,能够识别核磷蛋白/间变性淋巴瘤激酶(NPM-ALK)阳性间变性大细胞淋巴瘤(ALCL)患者复发风险高的情况。我们开发了一种流式细胞术(FCM)检测方法来定量罕见的ALK和CD30阳性ALCL细胞。当将ALCL细胞与正常外周血或骨髓混合时,对于所有三种测试细胞系,在添加浓度为10^(-5)时,可检测到高于背景水平的ALK和CD30阳性细胞。将该检测方法的灵敏度和成本与NPM-ALK的定量实时聚合酶链反应(PCR)进行了比较。FCM检测结果与NPM-ALK定量PCR结果相关。PCR的灵敏度比FCM至少高一个对数级。定量PCR比FCM更耗时且成本更高。对11例ALCL患者的骨髓或血液样本进行了两种方法的比较。使用抗ALK和CD30抗体的FCM能够灵敏且特异检测骨髓或血液中的循环ALCL细胞。该方法需要在更大的患者队列中进行测试,以确定其是否具有足够的灵敏度来替代定量PCR。